Topics

Akari Therapeutics’ Nomacopan Granted Orphan Drug Designation from the FDA for Treatment of Bullous Pemphigoid

09:44 EDT 13 Sep 2019 | Speciality Pharma Journal

NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for …

Original Article: Akari Therapeutics’ Nomacopan Granted Orphan Drug Designation from the FDA for Treatment of Bullous Pemphigoid

NEXT ARTICLE

More From BioPortfolio on "Akari Therapeutics’ Nomacopan Granted Orphan Drug Designation from the FDA for Treatment of Bullous Pemphigoid"

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...